



























Not for the first time in the recent years, but the hero 
again remains p53. Importantly that it was not from one 
single discovery but instead from several different 
discoveries and most were unexpected. Gudkov and co-
workers recently reported (also on line first) that p53, a 
tumor suppressor protein, recently renamed TP53, 
cooperated with DNA methylation to maintain the 
silencing of a large portion of the mouse genome. 
(Leonova KI, Brodsky L, Lipchick B, Pal M, 
Novototskaya L, Chenchik AA, Sen GC, Komarova 
EA, Gudkov AV. p53 cooperates with DNA 
methylation and a suicidal interferon response to 
maintain epigenetic silencing of repeats and noncoding 
RNAs. PNAS U S A. Epub 2012 Dec 10.) It was 
previously known that mammalian genomes contained 
various classes of interspersed and tandem repeat DNA 
sequences that were transcriptionally inactive. An 
essential unanswered question was why they are so 
many and why are they transcriptionally inactive? 
 
The answer to this question was recently provided by 
the Gudkov team. The transcription of these sequences 
was determined to be blocked by p53 in conjunction 
with DNA methylation. In p53-deficient, but not in p53 
wild-type mouse embryonic fibroblasts, treatment with a 
DNA demethylating agent  caused  massive  transcription 
 
 



























of short interspersed nuclear elements. These elements 
that were transcribed are near-centromeric satellite 
DNAs consisting of tandem repeats and multiple 
species of noncoding RNAs. Amazingly, the abundance 
of these transcripts exceeded the level of beta-actin 
mRNA by more than 150-fold. Accumulation of these 
transcripts, was accompanied by a strong, endogenous, 
apoptosis-inducing type I IFN response. This work was 
recently discussed in detail [1, 2]. This phenomenon, 
which Gudkov and co-workers named "TRAIN" (for 
"transcription of repeats activates interferon"), was 
observed in spontaneous tumors in two models of 
cancer-prone mice. The authors proposed that p53 and 
IFN cooperate to prevent accumulation of cells 
containing activated repeats and provide a plausible 
explanation for the deregulation of IFN function 
frequently observed in tumors. Therefore, p53 and IFN 
are key for genetic stability and therefore relevant to 
both tumorigenesis and aging.  
 
This phenomenon may be linked to another discovery 
about the role of p53 and INF in long-lived and cancer-
resistant rodents.  Gurbunova et al [3] demonstrated that 
in the blind mole rat Spalax, a small subterranean rodent 
which is distinguished by its adaptations to life 
underground, there was a remarkable longevity (with a 
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Abstract: The  P53  gene  and  it  product  p53  protein  is  the  most  studied  tumor  suppressor,  which  was  considered  as
oncogene for two decades until 1990. More than 60 thousand papers on the topic of p53 has been abstracted in Pubmed.
What  yet  could  be  discovered  about  its  role  in  cell  death,  growth  arrest  and  apoptosis,  as well  as  a mediator  of  the
therapeutic effect of anticancer drugs. Still during recent few years even more amazing discoveries have been done. Here
we  review  such  topics  as  suppression  of  epigenetic  silencing  of  a  large  number  of  non‐coding  RNAs,  role  of  p53  in
suppression  of  the  senescence  phenotype,  inhibition  of  oncogenic  metabolism,  protection  of  normal  cells  from
chemotherapy and even tumor suppression without apoptosis and cell cycle arrest. 
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maximum documented lifespan of 21 years), and 
resistance to spontaneous cancer induction. Spontane-
ous tumors have never been observed in these rodents.  
Cells obtained from blind mole rats proliferated for 7-20 
population doublings, after which the cells began 
secreting IFN-beta, and the cultures underwent necrotic 
cell death. In another long-lived and cancer-resistant rat 
model, the release of IFN-beta was determined to result 
in the sequestration of p53 and Rb-rescued necrotic cell 
death. The precise link between two discoveries needs 
to be further elucidated. Noteworthy, IFN-beta is 
currently undergoing phase I clinical trials in various 
drug combinations [4]. 
 
Next we discuss a third phenomenon published in 
summer of 2012. It was shown that hypoxia, by 
inhibiting mTOR in human cells, prevented the 
development of senescent phenotype in non-dividing 
but not senescent cells [5].  mTOR is known to drive 
cell senescence in culture [6-9] and its inhibition 
extends the lifespan of mice [10-16].  
 
As recently proposed, aging is not caused by 
accumulation of DNA damage but is driven by 
signaling pathways such as TOR   [13-36]. Aging and 
age-related diseases are quasi-programs, an aimless 
continuation of developmental growth. The hyper-
function theory was initiated by the hypothesis that 
active growth-promoting pathway must drive aging 
instead of growth, if the cell cycle is blocked [37, 38]. 
This increases cellular functions, leading to 
hyperfunction, age-related diseases and malfunctions. 
This theory, Recently named “the hyperfunction 
theory”, this point of view is becoming increasingly 
accepted [17 ,39, 40]. 
 
Besides rapamycin and other rapalogs, mTOR is 
inhibited by p53 and hypoxia [5, 7]. Long-lived rats that 
live underground frequently experience hypoxia. Could 
hypoxia also contribute to their exceptional longevity? 
Also, it was known that fibroblasts from long-lived 
mutant mice exhibit lower mTOR activity after nutrient 
deprivation or oxidative stress [41]. 
 
Two recent papers demonstrated that rapamycin can 
increase life-span in p53- deficient mice, substituting 
p53 by rapamycin [42, 43]. This may be due to natural 
inhibition of mTOR by p53, as suggested recently, so 
rapamycin could potentially substitute for p53-
dependent mTOR inhibition and extend lifespan [44]. 
p53 may not only initiate cell cycle arrest (a condition 
suitable for conversion to senescence driven by mTOR), 
but may also suppress this conversion from arrest to 
senescence by inhibiting mTOR [7]. The choice 
between senescence and quiescence/apoptosis may be 
determined by inhibition of mTOR by p53 [5, 8, 45-50].  
  
But the most unexpected discovery was the tumor 
suppression observed in the absence of p53-mediated 
cell-cycle arrest, apoptosis, and senescence [51, 52]. 
What could this result in? Most scientists remain 
skeptical. Could this missing tumor-suppression activity 
be gerosupression by p53 as recently discussed [53]. 
But still this could be a very unique case in exceptional 
conditions and special mice. 
 
There were numerous exciting reports increasing the 
diverse roles of p53 as a tumor suppressor [54-75] 
emphasizing its functions in apoptosis [76-81] and 
especially prevention of p53-mediated apoptosis by 
HIF-1 through a secreted neuronal tyrosinase [82] cell 
cycle arrest [83-86]. p53 has also been shown to be 
involved in the inhibition of invasiveness [87], and 
interact with other  genes to suppress cancer [88], as 
well as suppress p63 to prevent induction of a pro-
invasive secretome [89]. Moreover p53 has been shown 
to regulate telomere function [90] and p53 can suppress 
telomere-driven tetraploidization [91]. Interesting 
breakthroughs were in the identification of p53 as 
inhibitor of metabolism, [58, 92-94] its role in 
autophagy, [95, 96] it roles in induction of necrosis [97] 
and other diverse activities [98-110]. 
 
In fact, some of metabolic effects of p53 are associated 
with gerosuppression by p53 [53]. Noteworthy, 
rapamycin, like p53, may not only suppress oncogenic 
metabolism but also decrease lactate production by 
cancer cells [111, 112]. 
 
Given that the PI3K/mTOR pathway is activated in both 
aging [13] and cancer [113-125], aging and cancer share 
such characteristics as an increased metabolism, 
anabolic phenotype and other metabolic features [126]. 
By themselves, aerobic cancer cell and stromal 
metabolism become therapeutic targets [127]. 
Additional promising cancer-specific targets are gluta-
minase [128] and PKM2 [126-134]. PKM2 expression 
is necessary for aerobic glycolysis and cell proliferation 
in vivo [129-134]. Pyruvate kinase M2 regulates glucose 
metabolism by functioning as a coactivator for hypoxia-
inducible factor 1 in cancer cells [129-135]. Cancer 
cells universally express the M2 isoform of the 
glycolytic enzyme pyruvate kinase (PKM2). Although 
isoform selective inhibition of PKM2 with small 
molecules is feasible and support the hypothesis that 
inhibition of glucose metabolism in cancer cells is a 
viable strategy to treat human malignancy [125], the 
cancer-selectivity of PKM2 was recently doubted [136]. 
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But here is a new twist: p53 may protect cells lacking 
p53 (all normal cells), thus in theory decreasing side 
effects, without decreasing the therapeutic effects 
against cancer cells lacking p53. Thus, it was shown 
that p53-mediated senescence impairs the apoptotic 
response to chemotherapy and clinical outcome in 
breast cancer [137]. But here is a silver edge of the 
cloud [138]. By inducing cytostatic levels of p53 and 
causing quiescence, we can protect normal cells from 
chemotherapy, without protection of cancer cells 
lacking p53. Protection of normal cells was called 
cyclotherapy [139-142]. Protection of normal cells by 
induction of p53 was further confirmed recently [143-
147]. 
 
 Finally, the role of p53 in somatic cell reprogramming 
was recently discussed in detail [148-153].  
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